Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CITE study of routine subcutaneous allergen immunotherapy in birch pollen and house dust mite allergy
NL-OMON36931Phase 4Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Sep 2012
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of allergenic extract of birch and House dust mite allergen extract in allergic rhinitis (AR), house dust mite allergy, birch pollen allergy and 1 more (3 arms), sponsored by Erasmus MC. Primary endpoints: Nasal challenge-defined SIT responsiveness in inhalant allergy and Oral challenge-defined responsiveness for birch pollen-associated food allergy. Started Sep 2012; status: active, not recruiting.
02
Drugs
allergenic extract of birchHouse dust mite allergen extract
03
Conditions
allergic rhinitis (AR)house dust mite allergybirch pollen allergyPollen Food Allergy Syndrome (PFAS)
Beyond the preview
Go deeper on NL-OMON36931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36931.